Academic and commercial trials are run through the Haemato-oncology Unit. Trials that are currently recruiting are listed below under each disease category.
Please email us for more information about our haemato-oncology clinical trials.
Acute myeloid leukaemia (AML) trials
- IDH2 inhibitor study – for adults with AML with an IDH2 mutation over 59 years of age who have disease relapse or persistence despite two different types of therapy. We offer IDH2 mutation testing for patients who may go into this study (either here or at their local specialist hospital) – see Haematology Diagnostics page
- IDH2 inhibitor trial for older adults with untreated AML with an IDH2 mutation. This is a randomised trial with azacitidine given with or without an oral IDH2 inhibitor
- Trial of MDM2 antagonist in combination with intensive chemotherapy for relapsed/refractory AML in fit adults
- AML19 for untreated patients aged 18-60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
- AML18 for untreated patients aged over 60 years with AML. Looking at one vs two doses of gemtuzumab ozogamicin with standard chemotherapy
Acute lymphoblastic leukaemia (ALL) trials
- UKALL2011 trial for young adults aged 18-24 years with untreated ALL, looking at different doses of steroids and high dose methotrexate
- UKALL2014 trial for adults aged 25-60 years with untreated ALL, looking at the addition of rituximab antibody therapy to standard chemotherapy
- UKALL60+ trial for adults aged 60 years or more with untreated ALL, looking at chemotherapy of various intensities
Chronic lymphoid leukaemias
- Randomised clinical trial comparing R-FC to R-Ibrutinib in treatment naïve CLL patients with intact TP53
- Randomised clinical trial comparing Ibrutinib to Acalabrutinib in patients with previously treated CLL with ATM or TP53 loss
- A dose-finding study of single agent idelalisib in the treatment of double-refractory follicular lymphoma
- A clinical trial of ibrutinib, lenalidomide and rituximab in patients with relapsed/refractory DLBCL
Myelodysplastic syndromes and other myeloid disorders
For patients with low blood counts of uncertain cause we have a gene sequencing study to test whether any genes are mutated.
- An immunotherapy trial for patients with relapsed myeloma, combining daratumumab with a checkpoint inhibitor. Patients who do not respond to this combination go on to receive pomalidomide and dexamethasone in addition
- A dose-finding study of a next generation thalidomide analogue
- MUK7 – a randomised study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and cyclophosphamide in patients with relapsed myeloma
- MUK8 – a randomised study comparing cyclophosphamide and dexamethasone with ixazomib, cyclophosphamide and dexamethasone in patients with relapsed myeloma
- iTIMM – an imaging study for newly diagnosed patients with myeloma that requires therapy which will include a stem cell transplant. Patients undergo a PET/CT scan and whole body diffusion weighted MRI at diagnosis, and then a further MRI after initial therapy and again after transplant